It wasn't as much a "swipe" as it was an observation that the Chinese government has partnered with a US company involved with researching PS-targeting derivatives that PPHM "allegedly" has the rights to develop.
Last time I checked, patent infringement wasn't high on the list of concerns in Taiwan.
For more examples of why refusing to partner or collaborate with an ex-US partner will hurt PPHM in the future, see Sorafenib sales in India.
The US Gov't is running PPHM now IMO. Dead money until SUNRISE reads out.